Aruna Kamineni, PhD, MPH, came to Kaiser Permanente Washington Health Research Institute in 2009 with a wealth of experience in chronic disease epidemiology. Dr. Kamineni has expertise in using case-control methods to evaluate screening efficacy, and her research focuses on addressing evidence gaps for clinical guidelines, particularly for cervical and colorectal cancer prevention. A substantial portion of her work has focused on developing infrastructure and methods for research using electronic clinical and administrative health care data.
Since 2011, Dr. Kamineni has participated in the National Cancer Institute’s Population-based Research to Optimize the Screening Process (PROSPR) consortium to evaluate and improve cancer screening in U.S. community settings. As a principal investigator for multisite cervical and colorectal cancer PROSPR Research Centers, Dr. Kamineni is leading and collaborating on work to determine how to optimally use screening tests and consider how to tailor screening for population subgroups.
Dr. Kamineni’s research goals include studying the impact of human papillomavirus (HPV) DNA testing and HPV vaccination on cervical cancer and screening programs. Multidisciplinary collaboration is a valued and important driver of Dr. Kamineni’s research and she embraces a team science approach to optimizing cancer prevention.
Cervical cancer; colorectal cancer; screening; disparities
Electronic clinical and administrative data infrastructure development for research; case-control studies; team science
Feldman S, Lykken JM, Haas JS, Werner CL, Kobrin SC, Tiro JA, Chubak J, Kamineni A. Factors associated with timely colposcopy following an abnormal cervical cancer test result. Prev Med. 2022 Oct 18;164:107307. doi: 10.1016/j.ypmed.2022.107307. [Epub ahead of print]. PubMed
Kamineni A, Doria-Rose VP, Chubak J, Inadomi JM, Corley DA, Haas JS, Kobrin SC, Winer RL, Lafata JE, Beaber EF, Yudkin JS, Zheng Y, Skinner CS, Schottinger JE, Ritzwoller DP, Croswell JM, Burnett-Hartman AN. Evaluation of harms reporting in U.S. cancer screening guidelines. Ann Intern Med. 2022 Sep 27. doi: 10.7326/M22-1139. Online ahead of print. PubMed
Chubak J, Dalmat RR, Weiss NS, Doria-Rose VP, Corley DA, Kamineni A. Informative presence in electronic health record data: a challenge in implementing study exclusion criteria. Epidemiology. 2022 Sep 16. doi: 10.1097/EDE.0000000000001542. Online ahead of print. PubMed
Chao CR, Chubak J, Beaber EF, Kamineni A, Mao C, Silverberg MJ, Tiro JA, Skinner C, Garcia M, Corley DA, Winer RL, Raine-Bennett T, Feldman S, Wheeler CM. Gaps in the screening process for women diagnosed with cervical cancer in four diverse US health care settings. Cancer Med. 2022 Sep 15. doi: 10.1002/cam4.5226. Online ahead of print. PubMed
Dalmat RR, Ziebell RA, Kamineni A, Phipps AI, Weiss NS, Breslau ES, Corley DA, Green BB, Halm EA, Levin TR, Schottinger JE, Chubak J. Risk of colorectal cancer and colorectal cancer mortality beginning ten years after a negative colonoscopy, among screen-eligible adults 76-85 years old. Cancer Epidemiol Biomarkers Prev. 2022 Sep 13:EPI-22-0581. doi: 10.1158/1055-9965.EPI-22-0581. [Epub ahead of print]. PubMed
Chubak J, Burnett-Hartman AN, Barlow WE, Corley DA, Croswell JM, Neslund-Dudas C, Vachani A, Silver MI, Tiro JA, Kamineni A. Estimating cancer screening sensitivity and specificity using healthcare utilization data: defining the accuracy assessment interval. Cancer Epidemiol Biomarkers Prev. 2022 Aug 2;31(8):1517-1520. doi: 10.1158/1055-9965.EPI-22-0232. PubMed
Beaber EF, Kamineni A, Burnett-Hartman AN, Hixon B, Kobrin SC, Li CI, Oliver M, Rendle KA, Skinner CS, Todd K, Zheng Y, Ziebell RA, Breslau ES, Chubak J, Corley DA, Greenlee RT, Haas JS, Halm EA, Honda S, Neslund-Dudas C, Ritzwoller DP, Schottinger JE, Tiro JA, Vachani A, Doria-Rose VP. Evaluating and improving cancer screening process quality in a multilevel context: the PROSPR II consortium design and research agenda. Cancer Epidemiol Biomarkers Prev. 2022 Aug 2;31(8):1521-1531. doi: 10.1158/1055-9965.EPI-22-0100. PubMed
Schottinger JE, Jensen CD, Ghai NR, Chubak J, Lee JK, Kamineni A, Halm EA, Sugg-Skinner C, Udaltsova N, Zhao WK, Ziebell RA, Contreras R, Kim EJ, Fireman BH, Quesenberry CP, Corley DA. Association of physician adenoma detection rates with postcolonoscopy colorectal cancer. JAMA. 2022 Jun 7;327(21):2114-2122. doi: 10.1001/jama.2022.6644. PubMed
Feigelson HS, Clarke CL, Van Den Eeden SK, Weinmann S, Burnett-Hartman AN, Rowell S, Scott SG, White LL, Ter-Minassian M, Honda SAA, Young DR, Kamineni A, Chinn T, Lituev A, Bauck A, McGlynn EA. The Kaiser Permanente Research Bank Cancer Cohort: a collaborative resource to improve cancer care and survivorship. BMC Cancer. 2022;22(1):209. doi: 10.1186/s12885-022-09252-6. PubMed
Haas JS, Cheng D, Yu L, Atlas SJ, Clark C, Feldman S, Silver MI, Kamineni A, Chubak J, Pocobelli G, Tiro JA, Kobrin SC. Variation in the receipt of human papilloma virus co-testing for cervical screening: individual, provider, facility and healthcare system characteristics. Prev Med. 2022 Jan;154:106871. doi: 10.1016/j.ypmed.2021.106871. Epub 2021 Nov 8. PubMed
Aruna Kamineni, PhD, MPH, discusses her recent study on how guidelines report screening risks.
Research informs care as Kaiser Permanente Washington, exceeding 80 percent screening rate, launches home-based 'FIT First' pilot.
Drs. Kamineni and Chubak are among leaders of 2 new large PROSPR awards from NCI for cervical and colorectal cancer screening research.
Read it in News and Events.
Managed Healthcare Executive, Dec. 8